Literature DB >> 18383079

The impact of postreperfusion syndrome on short-term patient and liver allograft outcome in patients undergoing orthotopic liver transplantation.

Ibtesam Hilmi1, Charles N Horton, Raymond M Planinsic, Tetsuro Sakai, Ramona Nicolau-Raducu, Daniela Damian, Silivu Gligor, Amadeo Marcos.   

Abstract

The greatest part of liver allograft injury occurs during reperfusion, not during the cold ischemia phase. The aim of this study, therefore, was to investigate how the severity of postreperfusion syndrome (PRS) influences short-term outcome for the patient and for the liver allograft. Over a 2-year period, 338 consecutive patients who presented for orthotopic liver transplantation (OLT) were included in this retrospective study. They were divided into 2 groups according to the severity of the PRS they experienced. The first group comprised 152 patients with mild or no PRS; the second group comprised 186 patients with significant PRS. Perioperative hemodynamic parameters, coagulation profiles, blood product requirements, incidence of infection, incidence of rejection and outcome data for both groups were collected and analyzed. There was no demographic difference between the groups except for age; group 2 had older patients than group 1 (54.94 +/- 9.07 versus 51.52 +/- 9.91, P = 0.001). Compared to group 1, group 2 patients required more red blood cell transfusions (11.31 +/- 10.90 versus 8.08 +/- 7.89 units, P = 0.002), more fresh frozen plasma transfusions (10.25 +/- 10.96 versus 7.03 +/- 7.64 units, P = 0.002), more cryoprecipitate (1.88 +/- 4.72 units versus 0.61 +/- 1.80 units, P = 0.001), and were more likely to suffer from fibrinolysis (52.7% versus 41.4%, P = 0.041). Interestingly, group 2 had a shorter average warm ischemia time than group 1 (33.19 +/- 8.55 versus 36.21 +/- 11.83 minutes, P = 0.01). Group 2 also required longer, on average, mechanical ventilation (14.95 +/- 29.79 versus 8.55 +/- 17.79 days, P = 0.015), remained in the intensive care unit longer (17.65 +/- 31.00 versus 11.49 +/- 18.67 days, P = 0.025), and had a longer hospital stay (27.29 +/- 32.35 versus 20.85 +/- 21.08 days, P = 0.029). Group 2 was more likely to require retransplantation (8.6% versus 3.3%, P = 0.044). In conclusion, the severity of PRS during OLT appears to be related to the outcome of patient and liver allograft. (c) 2008 AASLD.

Entities:  

Mesh:

Year:  2008        PMID: 18383079     DOI: 10.1002/lt.21381

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  57 in total

1.  Protection of the intrahepatic biliary tree by contemporaneous portal and arterial reperfusion: results of a prospective randomized pilot study.

Authors:  Umberto Baccarani; Anna Rossetto; Dario Lorenzin; Stefania Bidinost; Maria Laura Pertoldeo; Manuela Lugano; Vittorio Bresadola; Giorgio Della Rocca; Andrea Risaliti; Gian Luigi Adani
Journal:  Updates Surg       Date:  2012-07-07

Review 2.  Post reperfusion syndrome during liver transplantation: From pathophysiology to therapy and preventive strategies.

Authors:  Antonio Siniscalchi; Lorenzo Gamberini; Cristiana Laici; Tommaso Bardi; Giorgio Ercolani; Laura Lorenzini; Stefano Faenza
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

3.  Optical imaging for the assessment of hepatocyte metabolic state in ischemia and reperfusion injuries.

Authors:  Mette F la Cour; Shima Mehrvar; Joohyun Kim; Alicia Martin; Michael A Zimmerman; Johnny C Hong; Mahsa Ranji
Journal:  Biomed Opt Express       Date:  2017-09-08       Impact factor: 3.732

4.  Increase in post-reperfusion sensitivity to tissue plasminogen activator-mediated fibrinolysis during liver transplantation is associated with abnormal metabolic changes and increased blood product utilisation.

Authors:  Hunter B Moore; Angelo D'Alessandro; Ernest E Moore; Matthew Wither; Peter J Lawson; Benjamin R Huebner; Kirk Hansen; Rashikh Choudhury; Trevor L Nydam
Journal:  Blood Transfus       Date:  2019-02-04       Impact factor: 3.443

5.  Celsior versus University of Wisconsin preserving solutions for liver transplantation: postreperfusion syndrome and outcome of a 5-year prospective randomized controlled study.

Authors:  Francisco A García-Gil; María T Serrano; Lorena Fuentes-Broto; Juan Arenas; José J García; Antonio Güemes; Vanesa Bernal; Ana Campillo; Carlos Sostres; Juan J Araiz; Pablo Royo; Miguel A Simón
Journal:  World J Surg       Date:  2011-07       Impact factor: 3.352

6.  Postreperfusion syndrome, hyperkalemia and machine perfusion in liver transplantation.

Authors:  Damiano Patrono; Renato Romagnoli
Journal:  Transl Gastroenterol Hepatol       Date:  2019-09-11

7.  Isolated small bowel transplantation outcomes and the impact of immunosuppressants: Experience of a single transplant center.

Authors:  Ibtesam A Hilmi; Raymond M Planinsic; Ramona Nicolau-Raducu; Daniela Damian; Ali Al-Khafaji; Tetsuro Sakai; Kareem Abu-Elmagd
Journal:  World J Transplant       Date:  2013-12-24

8.  Eosinophils attenuate hepatic ischemia-reperfusion injury in mice through ST2-dependent IL-13 production.

Authors:  Yaochun Wang; Yang Yang; Meng Wang; Shuhong Wang; Jong-Min Jeong; Long Xu; Yankai Wen; Christoph Emontzpohl; Constance Lynn Atkins; Kevin Duong; Nicolas F Moreno; Xiaoyi Yuan; David R Hall; Wasim Dar; Dechun Feng; Bin Gao; Yong Xu; Zoltan Czigany; Sean P Colgan; J Steve Bynon; Shizuo Akira; Jared M Brown; Holger K Eltzschig; Elizabeth A Jacobsen; Cynthia Ju
Journal:  Sci Transl Med       Date:  2021-02-03       Impact factor: 17.956

9.  Postperfusion Syndrome in Cadaveric Liver Transplantations: A Retrospective Study.

Authors:  Bahar Aydınlı; Ümit Karadeniz; Aslı Demir; Çiğdem Yıldırım Güçlü; Dilek Kazancı; Rabia Koçulu; Candan Haytural; Ayşegül Özgök; Erdal Birol Bostancı; Ali Zorlu
Journal:  Turk J Anaesthesiol Reanim       Date:  2016-06-01

10.  Sympathetic withdrawal is associated with hypotension after hepatic reperfusion.

Authors:  Young-Kug Kim; Kichang Lee; Gyu-Sam Hwang; Richard J Cohen
Journal:  Clin Auton Res       Date:  2013-03-07       Impact factor: 4.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.